Latest

News

• BMEYE B.V. Selected as a Red Herring Top 100 Europe Technology Startup
  

  • June 9, 2010
    BMEYE B.V., the innovator of combined noninvasive, beat-to-beat blood pressure and cardiac output monitoring received the prestigious European Red Herring Top 100 Award 2010. Red Herring's Top 100 Europe list has become a mark of distinction for identifying promising new companies and entrepreneurs.

    "We are very proud to be selected as a Red Herring Top 100 company", said Rob de Ree, CEO of BMEYE, "it is a very valuable recognition for the organization as a whole and for the breakthrough technology that improves patient care and which will change medical practice". "This award further drives and inspires the BMEYE team to successfully implement programs to accelerate clinical adoption" "Choosing the companies with the strongest potential was by no means a small feat," said Alex Vieux, publisher and CEO of Red Herring. "After rigorous contemplation and discussion, we narrowed our list down from hundreds of candidates from across Europe to the Top 100 Winners. We believe BMEYE embodies the vision, drive and innovation that define a successful entrepreneurial venture. BMEYE should be proud of its accomplishment, as the competition was very strong." BMEYE B.V., is the premier provider and will set the standard of noninvasive, beat-to-beat, user-friendly cardiovascular monitoring systems, to improve patient care and reduce healthcare costs. BMEYE B.V., a Dutch based company in Amsterdam, develops and markets innovative medical technology with broad applications in a variety of clinical settings. The Nexfin(TM) family of monitors uses an easy to apply finger sensor to produce accurate beat-to-beat, noninvasive blood pressure and cardiac output data displayed on an intuitive touch screen.

Milestones

• BMEYE Receives CE Mark to Launch First Noninvasive Cardiovascular Monitor with Masimo Rainbow SET(c) Pulse CO-Oximetry(tm) Technology in Europe
  
  • January 21, 2010
    
• Canadian approval
  
  • August 1, 2008
    BMEYE received today the Medical Device License for the Nexfin monitor from Health Canada.
• FDA 510(K) Clearance for Nexfin
  
  • December 10, 2007
    BMEYE announced today that it has received 510(K) clearance from the U.S. Food and Drug Administration (FDA) to market Nexfin, their newly developed line of safe, precise and easy to use hemodynamic monitors.
• BMEYE announces CE Mark Approval
  
  • July 23, 2007
    BMEYE announced today that they have received CE Mark approval for Nexfin, their newly developed line of accurate and easy to use hemodynamic monitors. The Nexfin monitors provide accurate and easy to use continuous non-invasive blood pressure and cardiac output monitoring.

Other

News

• Bristol Surgeon Receives Almost 120,000 Pounds For Pioneering Research Project
• Explaining An Important Genetic Cardiovascular Risk Factor
• Study Identifies Risk Factors For Cardiovascular Events In Patients With Atherothrombosis
• Using Lower-Dose Heparin During Percutaneous Coronary Intervention Does Not Appear To Reduce The Risk Of Major Bleeding
• Live Surgical Master Class At Hammersmith Hospital Uses HD Medical Conferencing To Educate International Surgeons On Pioneering Heart Valve Surgery
• Machine Translates Brain Signals Into Words "Better Than Chance"
• Health Law Rollout Effects: Delivering 'Accountable' Care, Device Tax, Nursing Mothers
• The Optimal Set-Up For Obtaining The Best Breast Scan Image With Minimal Radiation Dose To The Patient
• Medtronic Gains Ce Mark For Enhanced Corevalve(R) Delivery Catheter System With Accutrak Stability Layer
• Official Opening Of New Facilities For Ground Breaking Molecular Diagnostics Company